aTyr Pharma (NASDAQ: LIFE) reported Q2 EPS of ($0.35), $0.02 worse than the analyst estimate of ($0.33).

“We have made important advancements in the development of our lead product candidate, ATYR1923, during the recent months,” said Sanjay Shukla, M.D., M.S., President and CEO of aTyr. “We have completed our Phase 1 clinical trial for ATYR1923 and are poised to initiate a clinical trial by the end of this year in patients with interstitial lung disease. Our research activities have substantially increased our translational knowledge and furthered our understanding of neuropilin-2 as a target to accelerate the clinical development of ATYR1923.”

For earnings history and earnings-related data on aTyr Pharma (LIFE) click here.